Male Breast Cancer (cont.)
Melissa Conrad Stöppler, MD
Melissa Conrad Stöppler, MD, is a U.S. board-certified Anatomic Pathologist with subspecialty training in the fields of Experimental and Molecular Pathology. Dr. Stöppler's educational background includes a BA with Highest Distinction from the University of Virginia and an MD from the University of North Carolina. She completed residency training in Anatomic Pathology at Georgetown University followed by subspecialty fellowship training in molecular diagnostics and experimental pathology.
Dennis Lee, MD
Dr. Lee was born in Shanghai, China, and received his college and medical training in the United States. He is fluent in English and three Chinese dialects. He graduated with chemistry departmental honors from Harvey Mudd College. He was appointed president of AOA society at UCLA School of Medicine. He underwent internal medicine residency and gastroenterology fellowship training at Cedars Sinai Medical Center.
William C. Shiel Jr., MD, FACP, FACR
Dr. Shiel received a Bachelor of Science degree with honors from the University of Notre Dame. There he was involved in research in radiation biology and received the Huisking Scholarship. After graduating from St. Louis University School of Medicine, he completed his Internal Medicine residency and Rheumatology fellowship at the University of California, Irvine. He is board-certified in Internal Medicine and Rheumatology.
In this Article
- Male breast cancer facts
- What is male breast cancer?
- How common is male breast cancer?
- What are causes and risk factors of male breast cancer?
- What are the different types of male breast cancer?
- What are male breast cancer symptoms and signs?
- How is male breast cancer diagnosed?
- What is staging of male breast cancer?
- What is the treatment for male breast cancer?
- What is the outcome (prognosis) of male breast cancer?
- Find a local Oncologist in your town
How common is male breast cancer?
Male breast cancer is a rare condition, accounting for only about 1% of all breast cancers. Statistics from the American Cancer Society suggest that in 2015, about 2,350 new cases of breast cancer in men would be diagnosed and that breast cancer would cause approximately 440 deaths in men (in comparison, almost 40,000 women die of breast cancer each year). Breast cancer is 100 times more common in women than in men. Most cases of male breast cancer are detected in men between the ages of 60 and 70, although the condition can develop in men of any age. A man's lifetime risk of developing breast cancer is about 1/10 of 1%, or one in 1,000. Breast cancer incidence rates in men have remained fairly stable over the past 30 years.
What are causes and risk factors of male breast cancer?
As with cancer of the female breast, the cause of cancer of the male breast has not been fully characterized, but both environmental influences and genetic (inherited) factors likely play a role in its development. The following risk factors for the development of male breast cancer have been identified.
Exposure to ionizing radiation has been associated with an increased risk of developing male breast cancer. Men who have previously undergone radiation therapy to treat malignancies in the chest area (for example, Hodgkin's lymphoma) have an increased risk for the development of breast cancer.
Hyperestrogenism (high levels of estrogen)
Men normally produce small amounts of the female hormone estrogen, but certain conditions result in abnormally high levels of estrogen in men. The term gynecomastia means that the male breasts are abnormally enlarged in response to elevated levels of estrogen. High levels of estrogens also can increase the risk for development of male breast cancer. The majority of breast cancers in men are estrogen receptor-positive (meaning that they have proteins on the surface of the cells that can receive and transport estrogen through the cell wall and into the interor of the cell.). Two conditions in which men have abnormally high levels of estrogen that are commonly associated with breast enlargement are Klinefelter's syndrome and cirrhosis of the liver. Obesity is also associated with elevated estrogen levels and breast enlargement in men. Certain medications can cause gynecomastia as a side effect when taken for long periods. These include several types of medicine used to treat high blood pressure, medicines to reduce stomach acid, valium, finasteride, medicines to treat prostate cancer, and others. Check the side effects of the medicines you take if you think you may be developing male breast tissue enlargement (gynecomastia).
Klinefelter's syndrome is an inherited condition affecting about one in 1,000 men. A normal man has two sex chromosomes (X and Y). He inherited the female X chromosome from his mother and the male Y chromosome from his father. Men with Klinefelter's syndrome have inherited an extra female X chromosome, resulting in an abnormal sex chromosome makeup of XXY rather than the normal male XY. Affected Klinefelter's patients produce high levels of estrogen and develop enlarged breasts, sparse facial and body hair, small testes, and the inability to produce sperm. Some studies have shown an increase in the risk of developing breast cancer in men with this condition. Their risk for development of breast cancer is markedly increased, up to 50 times that of normal men.
Cirrhosis (scarring) of the liver
Cirrhosis can result from chronic alcohol abuse, chronic viral hepatitis, or rare genetic conditions that result in accumulation of toxic substances within the liver. The liver produces important binding proteins that affect the transport and delivery of male and female hormones via the bloodstream. With cirrhosis, liver function is compromised, and the levels of male and female hormones in the bloodstream are altered. Men with cirrhosis of the liver have higher blood levels of estrogen and have an increased risk of developing breast cancer.
Epidemiologic studies have shown that men who have several female relatives with breast cancer also have an increased risk for development of the disease. In particular, men who have inherited mutations in the breast cancer-associated BRCA-2 gene have an increased risk for developing breast cancer, with a lifetime risk of about 6 in 100 for development of breast cancer. BRCA-2 is a gene on chromosome 13 that normally functions in suppression of cell growth. Mutations in this gene lead to an increased risk for development of breast, ovarian, and prostate cancers. A portion of breast cancers in men are thought to be attributable to BRCA-2 mutation. Mutations in the BRCA-1 gene, which has been associated with inherited breast cancers in women, increase the risk for male breast cancer to a lesser degree than mutations in BRCA-2 (lifetime risk of 1 in 100).
Other genetic mutations have also been associated with an increase in risk for breast cancer in men, including mutations in the PTEN tumor suppressor gene (Cowden’s syndrome), TP53 mutations (Li-Fraumeni syndrome), PALB2 mutations, and mutations associated with hereditary nonpolyposis colorectal cancer (Lynch syndrome).
Finasteride (Propecia, Proscar), a drug that has been used to treat baldness, as well as benign prostatic hyperplasia (prostate enlargement) and to prevent prostate cancer, may be associated with an increased risk for male breast cancer. During clinical trials for the drug, no increased risk was shown. However, over 50 cases of male breast cancer have been reported worldwide in men taking the drug. Further studies are needed to clarify whether a causal relationship between the drug and the disease actually exists.
Viewers share their comments
Find support and advances in treatment.